Objective-Previously, we have identified bone morphogenetic protein endothelial cell precursor-derived regulator (BMPER) to increase the angiogenic activity of endothelial cells in a concentration-dependent manner. In this project, we now investigate how BMPER acts in concert with key molecules of angiogenesis to promote blood vessel formation. Approach and Results-To assess the effect of BMPER on angiogenesis-related signaling pathways, we performed an angiogenesis antibody array with BMPER-stimulated endothelial cells. We detected increased basic fibroblast growth factor (bFGF/FGF-2) expression after BMPER stimulation and decreased expression of thrombospondin-1. Additionally, FGF receptor-1 expression, phosphorylation, FGF signaling pathway activity, and cell survival were increased. Consistently, silencing of BMPER by small interfering RNA decreased bFGF and FGF receptor-1 expression and increased thrombospondin-1 expression and cell apoptosis. Next, we investigated the interaction of BMPER and the FGF signaling pathway in endothelial cell function. BMPER stimulation increased endothelial cell angiogenic activity in migration, Matrigel, and spheroid assays. To block FGF signaling, an anti-bFGF antibody was used, which effectively inhibited the proangiogenic BMPER effect. Accordingly, BMPER-silenced endothelial cells under bFGF stimulation showed decreased angiogenic activity compared with bFGF control. We confirmed these findings in vivo by subcutaneous Matrigel injections with and without bFGF in C57BL/6_Bmper +/− mice. Aortic ring assays of C57BL/6_Bmper +/− mice confirmed a specific effect for bFGF but not for vascular endothelial growth factor. Conclusions-Taken together, the proangiogenic BMPER effect in endothelial cells is mediated by inhibition of antiangiogenic thrombospondin-1 and enhanced expression and activation of the FGF signaling pathway that is crucial in the promotion of angiogenesis. (C.P.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
T o identify novel therapeutic approaches for adult pathological conditions, such as inflammatory disorders, cancer, retinopathy, atherosclerosis, or ischemic heart disease, it is essential to understand the molecular and cellular mechanism of blood vessel formation. 1 During embryonic development, the process of angiogenesis, that is, the formation of new blood vessels from preexisting ones, is highly important and tightly regulated by a multitude of intra-and extracellular proteins. 2 Of interest, some of the growth factors and signaling cascades that are active during embryonic vascular development have been shown to be reactivated during adult disease, as well as in regeneration processes, indicating their therapeutic potential. 3, 4 To achieve a complex, highly branched vasculature endothelial cell functions, such as migration, proliferation and sprout formation have to be fine-tuned by interacting pro-and antiangiogenic signals. 1, 5 For example, vascular endothelial growth factor (VEGF) signaling enhances expression of delta-like ligand 4 in endothelial tip cells, which in turn increases Notch cleavage in neighboring stalk cells. Notch cleavage leads to decreased VEGF receptor-2 expression and, subsequently, to the formation of a new capillary sprout. 1 The bioavailability of the potent angiogenesisinducer VEGF itself is regulated by antiangiogenic proteins, such as thrombospondin-1 (TSP-1), which is a nonstructural extracellular protein that acts on the cell surface together with other matricellular proteins to regulate cell interactions with the environment. 6 Besides the VEGF pathway, the superfamily of fibroblast growth factors (FGFs) is wellknown as potent inducer of neovascularization. In humans and mice, 22 FGF ligands and 4 tyrosine kinase highaffinity FGF receptors (FGFR1-4) have been identified; however, in endothelial cells, FGFR1 is the predominantly expressed FGFR. 7, 8 Regarding the cardiovascular system, administration of basic FGF (bFGF) has been shown to exert a protective effect on cardiac myocytes and to act as survival factor on endothelial cells and vascular smooth muscle cells. 9 Furthermore, clinical trials have revealed a positive but transient effect of bFGF on revascularization and angiogenesis. 7, 10, 11 In addition to the FGF and VEGF growth factors, other growth factor families, such as the transforming growth factor-β (TGF-β) superfamily comprising the bone morphogenetic proteins (BMPs), contribute to the proper orchestration of blood vessel formation. 12, 13 BMPs are extracellular proteins that signal through cell surface complexes of heterodimeric transmembrane serine/ threonine kinase receptors. On activation of the receptor, Smad 1/5 transcription factors become phosphorylated and translocate to the nucleus where they modulate gene expression. 14 Besides this Smad-dependent pathway, BMPs also phosphorylate other Smad-independent signaling cascades, such as MAP kinases/Erk and phosphoinositide 3-kinase (PI3K)/Akt pathways. 12 In line with a key role for BMPs in vascular development loss of function models of BMP ligands, the BMP receptors, or Smad 1/5, show early embryonic lethality as a result of disturbed mesoderm development and thus reduced vasculature. 12, 15, 16 BMP signaling is highly regulated in the extracellular space by BMP modulators, such as BMP endothelial cell precursor-derived regulator (BMPER). BMPER, the vertebrate homologue of Drosophila crossveinless-2, is a secreted glycoprotein that contains 5 cysteine-rich domains followed by a von Willebrand factor D domain and a trypsin inhibitor domain. 17 For BMPER, either pro-or anti-BMP effects have been reported that are dependent on the concentration and availability of BMP ligands, as well as other BMP modulators, such as chordin or twisted gastrulation. [18] [19] [20] Originally, BMPER was first identified in a screen for differentially expressed proteins in embryonic endothelial precursor cells, which overall emphasizes that BMPER plays a role in endothelial cell biology. 17 During the last few years, BMPER has emerged to be in the focus of interest in vascular biology, including endothelial cell inflammation, 21 atherosclerosis, 22 and angiogenesis. 18, [23] [24] [25] Regarding angiogenesis, we and others have previously shown that BMPER may enhance BMP signaling and the angiogenic response of endothelial cells in a concentration-dependent manner. 19, 23 Along the same line, BMPER was recently shown to be indispensable for normal coronary artery plexus formation during mouse embryonic development. 26 Collectively, these data demonstrated that BMPER exerts an anti-inflammatory and a proangiogenic effect on endothelial cells. However, which angiogenic downstream target genes are regulated and activated by BMPER to facilitate enhanced endothelial cell activity has not been investigated to date. In this study, we now aimed to investigate how BMPER interacts with key angiogenesis-related proteins to activate endothelial cell function in angiogenesis. Therefore, we stimulated endothelial cells with proangiogenic BMPER concentrations and performed a Proteome Profiler Angiogenesis Antibody Array that revealed candidates for further analysis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

BMPER Enhances bFGF and Reduces TSP-1 Expression in Endothelial Cells
To assess the effects of BMPER on angiogenesis-related signaling pathways, human umbilical venous endothelial cells (HUVECs) were stimulated with recombinant BMPER protein for 24 hours, and afterward a Proteome Profiler™ human angiogenesis antibody array was performed. After BMPER stimulation, bFGF was the most upregulated protein among 55 angiogenesis-related proteins ( Figure 1A ). The proteome array results were confirmed by quantitative real-time PCR and Western blot analysis of HUVECs incubated with increasing BMPER concentrations. Consistently, bFGF expression was enhanced at the mRNA (126%) and protein (189%) levels after BMPER stimulation ( Figure 1B and 1D). Of interest, expression of the antiangiogenic TSP-1 was reduced at the mRNA (74%) and protein (39%) levels ( Figure 1C ). Additionally, we used human lung microvascular endothelial cells to prove that the observed BMPER effect is not restricted to HUVECs. Indeed, we detected increased bFGF expression ( Figure 1E ; Figure IA and IC in the onlineonly Data Supplement) and decreased TSP-1 expression in human lung microvascular endothelial cells after BMPER stimulation ( Figure 1E ; Figure IB in the online-only Data Supplement). Together, these data indicate that BMPER increases the angiogenic potential of endothelial cells, on the one hand, via reduction of antiangiogenic TSP-1 expression and, on the other hand, by enhancing proangiogenic bFGF expression.
BMPER-Induced Proangiogenic Endothelial Cell Function Is Dependent on FGF Signaling
We hypothesized that BMPER-induced endothelial cell proangiogenic activity is dependent on bFGF. Therefore, we performed several functional cell culture assays and blocked bFGF with a neutralizing bFGF antibody (α-bFGF; Figure 2 ; Figure To ascertain that the α-bFGF antibody effect is restricted to bFGF, we also stimulated HUVECs with VEGF alone or in combination with the α-bFGF antibody and observed no difference ( Figure 2B ; Figure ID and IE in the online-only Data Supplement). Furthermore, endothelial cell migration quantified by use of a modified Boyden chamber assay confirmed bFGF-dependence for the proangiogenic BMPER effect ( Figure 2D ). In the 3D spheroid sprouting assay, bFGF and BMPER stimulation significantly enhanced HUVEC sprout formation, and addition of the α-bFGF antibody reduced this effect ( Figure 2C and 2E). Altogether, inhibition of bFGF by a neutralizing α-bFGF antibody inhibited BMPER-stimulated proangiogenic endothelial cell activity in functional endothelial cell culture assays.
BMPER Activates the FGF Signaling Pathway
Recently, experiments in zebrafish revealed that inhibition of transcription factors dlx3b/4b by morpholinos resulted in decreased BMPER and FGFR expression in the developing zebrafish embryo. 27 Interestingly, coinjection of BMPER mRNA together with dlx3b/4b morpholinos restored FGFR expression, indicating that BMPER also regulates the expression of FGF receptors. To investigate whether the same mechanism was also active in mammalian cells, we investigated FGFR1-4 expression in BMPER-stimulated endothelial cells ( Figure IIA -IID in the online-only Data Supplement). By using quantitative real-time PCR, we detected significantly increased FGFR1 and FGFR2 expression ( Figure  IIA and IIB in the online-only Data Supplement), whereas FGFR3 expression was not regulated and FGFR4 expression showed only a tendency to rise in response to BMPER stimulation ( Figure IIC and IID in the online-only Data Supplement). As FGFR1 is the predominant FGF receptor in endothelial cells, 8 we focused on FGFR1 protein expression. We confirmed increased FGFR1 protein expression in BMPER-stimulated HUVECs and human lung microvascular endothelial cells by western blot ( Figure 3A ; Figure IIG and IIH in the online-only Data Supplement). To ascertain whether BMPER promotes FGFR1 and bFGF expression by transcriptional regulation or by posttranscriptional stabilization, we blocked de novo transcription with actinomycin D ( Figure IIIA -IIID in the online-only Data Supplement). Western blot and real-time PCR analysis revealed that BMPER failed to increase bFGF and FGFR1 expression if de novo transcription was inhibited, which clearly suggests a transcriptional regulation. Given that BMPER enhanced bFGF and FGFR1 expression, we next investigated whether FGF signaling pathway activity was increased. Indeed, BMPER-stimulated HUVECs showed increased Akt and Erk1/2 phosphorylation compared with control ( Figure 3B ). Similarly, the in situ proximity ligation assay revealed more phosphorylated FGFR1 after bFGF or BMPER stimulation in the cytosol ( Figure 3C ). Of interest, Coleman et al have recently shown that stimulation of pancreatic stellate cells with bFGF led to increased nuclear bFGF/FGFR1 colocalization. 28 Therefore, we next examined the localization of FGFR1 in endothelial cells after BMPER stimulation ( Figure 3D ; Figure IIIF in the online-only Data Supplement). At baseline conditions, a certain amount of FGFR1 is located in the nuclear region, whereas in the presence of the α-bFGF antibody, nuclear localization of FGFR1 is reduced. As positive control for FGFR1 activation, HUVECs were stimulated with bFGF, which resulted in increased nuclear FGFR1 localization. Along the same line, BMPER stimulation enhanced FGFR1 nuclear localization.
Because BMPER increased FGF signaling pathway activity, we next aimed to analyze whether downstream targets of the FGF signaling pathway, namely transcription factors B-cell lymphoma 2 (Bcl-2) and Bcl-2 antagonist of cell death (BAD), were regulated by BMPER in HUVECs. Apoptotic BAD expression is known to be downregulated by FGF signaling, whereas antiapoptotic Bcl-2 expression is upregulated. 29, 30 Along the same line as BMPER-stimulated HUVECs showed increased bFGF and FGFR1 expression, BAD expression is reduced (59%; Figure IIF in the online-only Data Supplement), whereas Bcl-2 expression is increased (139%; Figure 3E ; Figure IIE in the online-only Data Supplement). Likewise, endothelial cell viability was increased ( Figure 3F ) and cell apoptosis showed a tendency to fall in response to BMPER stimulation ( Figure IIIE in the online-only Data Supplement). Collectively, we found that BMPER increased the expression of FGFR1 and the activity of the FGF signaling pathway and along this line enhanced cell survival.
Silencing of BMPER Decreases FGF Signaling and Increases TSP-1 Expression and Cell Apoptosis
As BMPER-stimulated HUVECs showed upregulation of the FGF signaling pathway, we hypothesized that silencing of BMPER leads to bFGF and FGFR1 downregulation. Knockdown efficiency for the 2 BMPER-specific small interfering RNAs (B1 and B2) compared with scrambled control small interfering RNA were quantified 48 hours post transfection on mRNA and protein levels ( Figure 4A ) Indeed, in BMPER-silenced endothelial cells, bFGF expression was decreased as detected in the angiogenesis proteome profiler array, as well as by Western blot analysis ( Figure 4A and 4B, left). Accordingly, we detected reduced expression of FGFR1 on protein (Figure 4B , middle) and mRNA levels in BMPER-deficient HUVECs ( Figure IVA in the online-only Data Supplement). Vice versa we found that BMPER-silenced HUVECs showed enhanced antiangiogenic TSP-1 protein expression ( Figure 4B, right) . Accordingly, FGF signaling pathway activity was reduced as shown by Western blot analysis for Akt and Erk1/2 phosphorylation of BMPER-deficient endothelial cells ( Figure 4C ). Consistent with downregulated bFGF and FGFR1 and upregulated TSP-1 that is known to induce apoptosis, 31 we found decreased cell viability as well as increased cell apoptosis in BMPER-silenced endothelial cells ( Figure 4D ). Together, these data emphasize that lack of BMPER in endothelial cells induces an antiangiogenic expression profile by increasing antiangiogenic TSP-1, as well as reducing proangiogenic bFGF and FGFR1 expression.
BMPER-Silenced Endothelial Cells Show Reduced Response to bFGF Stimulation
Given that silencing BMPER in endothelial cells resulted in an antiangiogenic expression profile, we next asked whether BMPER-deficient HUVECs can respond to bFGF stimulation. Forty-eight hours post-small interfering RNA transfection, we performed the in vitro Matrigel capillary-like sprouting assay that confirmed reduced sprouting and branch point formation of BMPER-silenced endothelial cells compared with control cells (Figure 5A and 5B; Figure IVB in the online-only Data Supplement). As expected, bFGF stimulation of small interfering RNA control-transfected endothelial cells resulted in increased angiogenic sprout formation compared with basal conditions. However, BMPER-silenced endothelial cells only partially responded to bFGF stimulation. To further support this notion, we performed endothelial cell migration assays ( Figure 5C ) and 3D collagen gel spheroid sprouting assays ( Figure 5D and 5E ). Consistently, we obtained the same findings as in the Matrigel capillary-like sprouting assay. Taken together, these data demonstrate that BMPER-silenced endothelial cells do not fully respond to bFGF stimulation, indicating that the antiangiogenic state of BMPER-silenced endothelial cells is partly independent of bFGF availability, but is caused by reduced expression of FGFR1 and increased expression of TSP-1.
FGF-Induced Angiogenesis Is Dependent on BMPER Ex Vivo and In Vivo
To confirm our in vitro findings that bFGF-induced angiogenesis is decreased if BMPER expression is reduced, we next investigated the in vivo relevance in BMPER heterozygous C57BL/6 mice. Because BMPER −/− animals die at birth, 19 we examined the differences of wild-type versus BMPER +/− mice in the ex vivo aortic ring assay ( Figure 6A and 6B; Figure  IVC in the online-only Data Supplement) and the in vivo Matrigel plug assay ( Figure 6C and 6D) . For the aortic ring assay, thoracic aortae from C57BL/6_BMPER +/− and wildtype littermate mice were removed, cut into rings, embedded into a collagen gel, and stimulated with or without bFGF or VEGF for 9 days (Figure 6A and 6B) . Under basal conditions, few sprouts emerge from the aortic rings and we observed no difference between BMPER +/− and wild-type animals. In contrast, after bFGF stimulation, aortic ring sprout formation was reduced by >50% in BMPER +/− mice ( Figure 6B ). To prove that this effect was specific for the FGF signaling pathway, aortic rings were also stimulated with VEGF as a control. Indeed, reduced BMPER expression had no effect on VEGFinduced aortic ring sprout formation. As a prototypic in vivo angiogenesis assay, we performed the mouse Matrigel plug assay. Mice were subcutaneously injected with pure Matrigel or Matrigel mixed with bFGF and VEGF, respectively. After 10 days, mice were euthanized, Matrigel plugs were embedded in paraffin, and histological analysis was performed. Consistent with our previous findings, endothelial cell ingrowth into the Matrigel plug was significantly reduced in BMPER +/− mice compared with wild-type littermates ( Figure 6C and 6D). In line with our in vitro findings that BMPER-silenced endothelial cells only partially respond to bFGF stimulation ( Figure 5) , we observed only a partially increased endothelial cell ingrowth in bFGF Matrigel plugs of BMPER +/− mice compared with wild-type control bFGF Matrigel plugs. Again, reduced BMPER expression had no effect on VEGFinduced endothelial cell ingrowth. To confirm endothelial cell specificity of ingrowing cells, a CD31-Cy3 staining was performed. Indeed, cellular ingrowth into the Matrigel plug consisted mainly of CD31 (stained in red) and DAPI (nuclei in blue) double positive cells ( Figure 6D ; Figure IVD in the online-only Data Supplement). Collectively, these findings confirm that BMPER-deficiency impairs the proangiogenic FGF-signaling pathway, which results in reduced angiogenesis in vivo. 
Discussion
In recent years, BMPER has moved into focus of increasing interest in endothelial cell biology. 18, 23, 25, 26, 32, 33 In regard to angiogenesis, we have previously shown that BMPER is necessary, as well as it augments endothelial cell function to form blood vessels in vitro and in vivo. 23, 25, 26 The results of the present study now demonstrate that BMPER promotes proangiogenic endothelial cell behavior via upregulation of the FGF signaling pathway and by downregulation of antiangiogenic TSP-1 expression (Figure 1-3) . Consistently, BMPER-deficiency leads to decreased FGF pathway signaling and enhanced TSP-1 expression, resulting in reduced proangiogenic behavior of endothelial cells in vitro and in vivo (Figure 4-6) .
During embryonic development, branched organs, such as the lung, the kidneys, large nerves, and the vasculature, are formed by patterning mechanisms that are activated by the same molecular pathways, including the FGF and the BMP signaling pathways. 34 Regarding angiogenesis, FGFs as well as BMPs have repeatedly been shown to enhance endothelial cell proliferation, migration, sprouting, and ultimately, blood vessel formation. 2, 7, [10] [11] [12] 35 Vice versa, FGF-2 inhibition has been shown to inhibit coronary artery stem formation in quail hearts during embryonic development. 36 Recently, a similar phenotype was reported for homozygous BMPER-deficient mice in coronary artery stem development. 26 Therefore, it is tempting to speculate that because of these similarities in the phenotype, an interaction between BMPER and the FGF signaling pathway in branching morphogenesis might occur during angiogenesis. Indeed, the results of the present investigation reveal that BMPER enhances bFGF expression in endothelial cells and that the proangiogenic effect of BMPER is dependent on bFGF. Consistently, in BMPER-silenced endothelial cells, bFGF expression is decreased. Furthermore, the angiogenic activity of BMPER-silenced endothelial cells is reduced in vitro and in vivo, but stimulation with bFGF can partially rescue their proangiogenic properties. Taken together, our results support the notion that BMPER promotes bFGF pathway activity and, along this line, angiogenic behavior of endothelial cells.
Previously, the BMP family member BMP-2 was shown to enhance the expression of FGFR1 in PC12 cells and to augment FGF-induced differentiation of these cells. Therefore, it was concluded that BMP-2 and FGF act in concert to regulate cell differentiation in the nervous system. 37 Along the same line, Esterberg and Fritz have shown that during zebrafish otic placode development, depletion of transcription factors dlx3b/4b result in decreased BMPER and FGFR expression. Interestingly, coinjection of BMPER mRNA together with dlx3b/4b morpholinos restores FGFR expression, indicating that BMPER acts upstream of FGF receptor expression. 27 In accordance, we detected increased FGFR1 expression in BMPER-stimulated endothelial cells and decreased FGFR1 expression in BMPERdepleted endothelial cells. Taken together, this is the first report demonstrating a connection between BMPER availability and FGFR1 expression in endothelial cells.
Given that BMPER upregulates bFGF and FGFR1 expression, we next investigated whether, accordingly, the FGF signaling pathway is activated. Therefore, we aimed to analyze that the FGF signaling pathway downstream targets transcription factor Bcl-2 30 and BAD, 38 as well as the localization of FGFR1 in endothelial cells. We confirmed increased antiapoptotic Bcl-2 expression and decreased proapoptotic BAD expression in HUVECs after stimulation with bFGF as well as with BMPER. These findings are in line with increased cell survival after bFGF treatment. 9 Basic FGF can localize directly to the nucleus where it promotes proliferation, differentiation, and functional activation in a variety of cell types. 39 Moreover, Coleman et al have recently shown that stimulation of pancreatic stellate cells with bFGF led to increased nuclear bFGF/ FGFR1 colocalization, which was followed by enhanced proliferation and invasion. 28 Similarly, we detected enhanced FGFR1 nuclear localization accompanied and increased phosphorylated FGFR in the cytosol of BMPER-stimulated HUVECs. Collectively, we found that BMPER promotes FGF signaling pathway activity by increased phosphorylation of FGFR1, downstream signaling pathway members Akt and Erk1/2, nuclear localization of FGFR1, regulation of Bcl-2 and BAD expression, and increased cell survival.
Besides positive regulators of angiogenesis, such as the FGF signaling pathway, inhibitors, such as TSP-1, play an important role in the regulation of angiogenesis. 40 TSP-1 is Figure 6 . Heterozygous C57BL/6_Bmper-deficient mice showed reduced endothelial cell proangiogenic activity after basic fibroblast growth factor (bFGF) stimulation in ex vivo aortic ring and in vivo Matrigel plug assays. Aortas from C57BL/6_Bmper +/− and wild-type mice were cut into rings, embedded in a collagen gel, and stimulated with bFGF (50 ng/mL) or vascular endothelial growth factor (VEGF; 50 ng/ mL) for 9 days. A, Representative confocal images of aortic rings stained for endothelial cells with Lectin-FITC (green). Scale bars: 200 μm. B, Quantification of aortic ring assay. Values are means±SEM; n=7, *P<0.02 vs wild-type control. #P<0.01 WT vs C57BL/6_Bmper +/− mice. C and D, Matrigel containing either recombinant bFGF, VEGF protein (200 ng/ mL), or control was injected subcutaneously into C57BL/6_Bmper +/− and WT mice. Matrigel plugs were harvested 10 days after implantation, fixed, sectioned, and stained. C, Quantification of Matrigel plugs. Values are means±SEM; n=9, *P<0.05 vs wildtype control. D, left, Representative micrographs of Matrigel plugs stained with hematoxilin and eosin (H&E). Scale bar: 100 μm. D, right, Representative micrographs of C57BL/6 WT and Bmper +/− Matrigel plugs stimulated with bFGF and stained with CD31-Cy3 (red) and DAPI to visualize nuclei (blue). Scale bar: 20 μm. a modular protein and consists of several protein domains, including a von Willebrand Factor type C and a procollagen domain. Because of its structure, TSP-1 belongs to the functional family of matricellular proteins that are defined as nonstructural extracellular proteins. Through its different domains, TSP-1 is able to interact simultaneously with different cell receptors, soluble cytokines and growth factors, extracellular matrix components, and proteases. 6 It inhibits angiogenesis by suppressing cell proliferation and migration and induces apoptosis. 31 Moreover, TSP-1 inhibits angiogenesis indirectly by binding proangiogenic factors, such as bFGF. 41 In the present study, we have shown that BMPER suppresses TSP-1 expression in endothelial cells and vice versa in BMPER-silenced endothelial cells TSP-1 expression is enhanced, whereas proangiogenic function is inhibited ( Figure V in the online-only Data Supplement). Taken together, BMPER regulates FGF-dependent angiogenesis at 2 levels. First, it controls expression of FGF pathway proteins, and second, it regulates an inhibitor of FGF signaling.
In the past application, overexpression of growth factors, such as FGF, has not proven to be clinically useful. The reasons for this disappointment are multifactorial, but obviously a single growth factor is not sufficient to promote angiogenesis efficiently. Induction of proangiogenic pathways at several levels and in a more indirect fashion as we have shown this for BMPER may be an option that should be explored in the future.
